Reviewed by Sarim Mir, MD — Board-Certified Neurologist, Mir Neurology (Hagerstown & Cumberland, MD)
Key takeaways
- 2026 has been a busy year for neurology, with new FDA approvals and decisions touching Alzheimer’s, Parkinson’s, MS, epilepsy, neuropathy, and sleep apnea.
- Some items are fully FDA-approved and available now; others are still investigational or under review and not yet on the market.
- Approval does not mean a treatment is right for you — eligibility depends on your diagnosis, history, and testing.
- This is a living summary that we update as new decisions are announced.
- Questions about whether any of these apply to your care? Mir Neurology in Hagerstown and Cumberland can help.
What changed
Each year the U.S. Food and Drug Administration (FDA) reviews new neurology treatments, and 2026 has already delivered several notable decisions. Below is a plain-English, news-style roundup organized by condition. We have kept each entry short and flagged what is FDA-approved versus still investigational, so you can see at a glance where things stand. None of this is a substitute for a conversation with your own neurologist.
Plain-English explainer
“FDA-approved” means the agency has reviewed the evidence and cleared a treatment for a specific use — it is available by prescription or procedure. “Priority review,” “under review,” or a “PDUFA date” means the FDA is still evaluating a treatment and has not yet decided. “Investigational” or “Phase 3” means a therapy is still being studied in trials and is not yet available outside of research. Keeping these labels straight matters, because headlines often blur them together.
What happened in 2026, by condition
Alzheimer’s disease. A subcutaneous (under-the-skin) autoinjector version of lecanemab moved through FDA review in 2026; the agency extended its review, pushing the decision date to later in the year. The FDA also approved an updated, slower titration schedule for donanemab designed to lower the risk of ARIA (amyloid-related imaging abnormalities, a brain-swelling or bleeding side effect seen on scans) while preserving benefit. Separately, AXS-05 — an oral therapy for agitation in Alzheimer’s dementia — has been under priority review. (Learn more about our Alzheimer’s disease and memory & cognitive care.)
Parkinson’s disease. Tavapadon, an investigational oral dopamine-receptor partial agonist from AbbVie, has a decision expected in the first half of 2026. It is not yet FDA-approved. (See our Parkinson’s disease care.)
Multiple sclerosis (MS). In January 2026, the FDA approved the first complex generic version of glatiramer acetate for relapsing MS, which may improve access and lower cost. In the pipeline, fenebrutinib reported data in primary progressive MS (PPMS), while tolebrutinib received a Complete Response Letter (CRL) — meaning the FDA declined to approve it in its current form and requested more information. (See our multiple sclerosis care.)
Epilepsy. The FDA approved an expanded pediatric indication for vagus nerve stimulation (VNS), a device-based therapy for hard-to-control seizures. Meanwhile, azetukalner, an investigational oral medication, continued in Phase 3 testing and is not yet approved. (See our epilepsy care and EEG testing.)
Neuropathy. The Neuralace Axon Therapy device received FDA clearance as a non-drug option being studied for painful peripheral neuropathy. (See our neuropathy treatment and EMG testing.)
Sleep apnea. Zepbound (tirzepatide) gained attention in 2026 for obstructive sleep apnea linked to obesity, reflecting growing interest in weight-based approaches to sleep-disordered breathing alongside standard therapies like CPAP.
What this means for you in Hagerstown & Cumberland
A new approval in the news does not automatically change your treatment plan — and many of these items are still investigational. What matters is whether a therapy fits your specific diagnosis, medical history, and goals. At Mir Neurology, Dr. Sarim Mir can review which developments are relevant to you and whether testing or a referral makes sense. Explore our full list of conditions we treat or meet Dr. Sarim Mir, MD.
Call (301) 797-7600 to request an appointment or visit mirneurology.com/book-appointment.
Frequently asked questions
Does FDA approval mean a treatment is right for me? No. Approval means a therapy is available for a defined use, but eligibility depends on your diagnosis, prior treatments, and individual risks. Your neurologist helps decide if it fits.
What is the difference between “approved” and “investigational”? Approved treatments have cleared FDA review and can be prescribed or performed. Investigational treatments are still being studied in clinical trials and are not yet available to the general public.
Why do you call this a “living summary”? Because FDA decisions continue throughout the year. We update this roundup as new approvals, reviews, and trial results are announced, so the details may change after publication.
This article is for general educational purposes only and is not medical advice. It does not promise any cure or specific outcome. Treatment availability and labeling can change. Always talk with a qualified neurologist about your individual situation.
Sources: Q1 2026 Clinical Recap: 7 FDA-Approved Treatments for Neurologists to Know, Previewing Expected FDA Decisions in Neurology for 2026
Need to talk to a neurologist about this?
Mir Neurology offers same-week appointments in Hagerstown & Cumberland, MD. No referral needed for most plans.
